Sugi Predict

Sugi Predict / Compounds / Ammonia Solution, Strong

Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL905935

CCCn1ncc2ccc(SC)cc21.N

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR2A P28223 5/20 0.44
▸ HTR2C P28335 5/20 0.44
▸ HTR2B P41595 4/20 0.44
▸ KMO O15229 8/20 0.43
▸ HTR1A P08908 2/20 0.38
▸ ADRA2A P08913 2/20 0.38
▸ ADRA2B P18089 2/20 0.38
▸ ADRA2C P18825 2/20 0.38
▸ HTR1D P28221 1/20 0.38
▸ HTR7 P34969 1/20 0.38
▸ HTR4 Q13639 1/20 0.38
▸ CYP1A2 P05177 1/20 0.36
▸ POLB P06746 1/20 0.35
▸ RECQL P46063 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ FGFR1 P11362 1/20 0.33
▸ QPCT Q16769 1/20 0.33
▸ SLC16A3 O15427 2/20 0.33
▸ SLC16A1 P53985 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fumaric Acid SCHEMBL8009277 0.88 KMO (0.47) HTR2AHTR2CHTR2BKMOPOLB
Ammonia Solution, Strong SCHEMBL906042 0.84 KMO (0.42) HTR2AHTR2CHTR2BKMOHTR1A
SCHEMBL8013345 0.82 HTR2A (0.52) HTR2AHTR2CHTR2BKMOHTR1A
SCHEMBL24908252 0.80 NOTUM (0.43) HTR2AHTR2CHTR2BKMOCYP1A2
Ammonia Solution, Strong SCHEMBL8009916 0.79 HTR2A (0.45) HTR2AHTR2CHTR2BKMOHTR1A
SCHEMBL8430529 0.78 KMO (0.64) HTR2AHTR2CHTR2BKMOHTR1A
SCHEMBL20769975 0.78 HTR2A (0.50) HTR2AHTR2CHTR2BKMOHTR1A
SCHEMBL14155061 0.78 HTR2A (0.61) HTR2AHTR2CHTR2BKMOHTR1A
SCHEMBL3099635 0.78 HTR2A (0.71) HTR2AHTR2CHTR2BKMOHTR1A
SCHEMBL6741175 0.78 HTR2A (0.46) HTR2AHTR2CHTR2BKMOHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110152272-A1 Treatment Of Incontinence PFIZER INC 2011-06-23 — — US disclosed
EP-2277513-A2 Treatment of incontinence with 5htc2 agonists Pfizer Inc. (US) 2011-01-26 — — EP disclosed
US-20080146583-A1 Treatment of Incontinence PFIZER INC 2008-06-19 — — US disclosed
EP-1620081-A2 TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS Pfizer Limited (GB) 2006-02-01 — — EP disclosed
US-20040235856-A1 Treatment of incontinence PFIZER INC 2004-11-25 — — US disclosed
WO-2004096196-A2 TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS PFIZER LIMITED (GB) 2004-11-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235856-A1 Treatment of incontinence HTR2C, HTR5A, ADRA2C HTR2A 6/4885HTR2C 1/4885HTR2B 10/4885
US-20110152272-A1 Treatment Of Incontinence HTR2C, HTR5A, ADRA2C HTR2A 6/4885HTR2C 1/4885HTR2B 10/4885
US-20080146583-A1 Treatment of Incontinence HTR2C, HTR5A, ADRA2C HTR2A 6/4885HTR2C 1/4885HTR2B 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.